FFAR1

(redirected from GPR40)

FFAR1

A gene on chromosome 19q13.1 that encodes a member of the GP40 family of G protein-coupled receptors that is a receptor for medium and long-chain free fatty acids. FFAR2 may be involved in the metabolic regulation of insulin secretion.
References in periodicals archive ?
The reason LCFA could mediate cell proliferation and survival was unknown, and it is probably related to bGPR40, GPR40 is one of the G protein-coupled receptors, and it could be activated by medium and long-chain fatty acids (Briscoe et al.
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
The company also presented Phase 3 data on the investigational compound fasiglifam, a potential first-in-class GPR40 agonist for the treatment of Type 2 diabetes, demonstrating the study's primary endpoint of change from baseline in HbA1c at week 24 was met.
Fasiglifam Data The presentation entitled "Efficacy and safety of fasiglifam (TAK-875), a GPR40 selective agonist, in Japanese Type 2 diabetes mellitus patients: a Phase 3, double-blind, placebo controlled, comparative study" includes findings from the CCT-003 study, which evaluated the efficacy and safety of the investigational compound fasiglifam 25 mg and 50 mg, administered once daily before breakfast for 24 weeks, in Japanese patients with Type 2 diabetes inadequately controlled by diet and exercise.
A putative link of PUFA, GPR40 and adult-born hippocampal neurons for memory.
TAK-875 is the first GPR40 agonist to reach late-stage (Phase 3) clinical development
These data, which were presented at the American Diabetes Association 71st Annual Scientific Sessions, demonstrated that the GPR40 agonist, at doses ranging from 6.
Although a new generation of antidiabetic drugs which target this receptor to promote insulin tolerance and production is currently being tested, until now little has been known about precisely how the expression of GPR40 is controlled
An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPCR research and is the first GPR40 agonist to reach late stage (Phase 3) clinical development.
GPR40 agonists have a mechanism of action for type 2 diabetes different from that of sulfonylureas (such as glimepiride).
TAK-875 is the first GPR40 agonist to reach clinical development, and completed studies have demonstrated glucose-lowering effects in patients with type 2 diabetes by stimulating glucose-dependent insulin secretion.
Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists